- Trial phase
- Phase 1
- Time to market
- IM-1617 is in Phase 1 dose-escalation; assuming successful development, potential approval would be several years away (likely 2029-2031 at the earliest).
- Why 3/10
- IM-1617 is in Phase 1 with no scheduled data readout or regulatory catalyst in the next 12 months. The stock's next major catalyst is varegacestat's PDUFA date on April 28, 2027, not IM-1617. As an early-stage asset in a multi-program company, IM-1617 alone is unlikely to drive a significant share-price move in the near term.
IM-1617 is an early Phase 1 asset with no publicly announced data readout date. The next major catalyst for Immunome overall is the varegacestat PDUFA decision on April 28, 2027. For IM-1617 specifically, watch for any initial safety/efficacy data from the Phase 1 trial, which could emerge in 2027 at a medical conference or corporate update.
Price Chart
Executive Summary
IM-1617 is a potential first-in-class antibody-drug conjugate (ADC) targeting an undisclosed receptor tyrosine kinase in advanced solid tumors, developed by Immunome Inc. (NASDAQ: IMNM). It uses Immunome's proprietary topoisomerase I inhibitor payload (HC74). The drug received IND clearance in April 2026 and the first patient was dosed in a Phase 1 first-in-human trial in June 2026. IM-1617 is one of several early-stage ADC candidates in Immunome's pipeline, which is led by varegacestat (desmoid tumors, PDUFA April 28, 2027). As a Phase 1 asset with no near-term binary catalyst, IM-1617 is a small part of the Immunome investment thesis at this stage.
How It Works
IM-1617 is an antibody-drug conjugate (ADC), a type of cancer therapy that works like a guided missile. It consists of an antibody that seeks out and binds to a specific protein (a receptor tyrosine kinase) found on the surface of solid tumor cells, attached to a powerful chemotherapy drug (HC74, a topoisomerase I inhibitor). Once the antibody binds to the cancer cell, the cell absorbs the ADC and releases the chemotherapy payload inside, killing the cancer cell while sparing most healthy tissue.
Trial Status
Phase 1 first-in-human trial initiated; first patient dosed June 11, 2026. The trial is evaluating IM-1617 in patients with advanced solid tumors. No interim data or readout date has been announced.
The Two-Sided Case
Upcoming Catalysts
- Initial Phase 1 safety/tolerability data from IM-1617 (no date announced; could emerge at a medical conference in 2027)
- IM-1021 updated data at ASH 2026 (December 14, 2026), not IM-1617 but relevant to Immunome's ADC platform thesis
- Varegacestat PDUFA target action date (April 28, 2027), Immunome's primary near-term catalyst
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Immunome Inc. 8-K IMNM ·Originating report